Zimmer Biomet Holdings (NYSE: ZBH) reported Q2 EPS of $1.59, $0.04 better than the analyst estimate of $1.55. Revenue for the quarter came in at $1.17 billion versus the consensus estimate of $1.19 billion.

Zimmer Biomet Holdings sees FY2015 EPS of $6.65-$6.80, versus prior guidance of $6.60-$6.80 and the consensus of $6.66.

"During the quarter, we completed our landmark combination to create Zimmer Biomet, marking a new era for our company and an unprecedented opportunity to drive our growth and value creation strategies," said David Dvorak, President and CEO of Zimmer Biomet. "With a broad and diversified musculoskeletal portfolio, Zimmer Biomet is well positioned to reach new heights of commercial and operational excellence, and to accelerate the pace of our innovation for the evolving healthcare landscape."

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.